Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Apr;114(8):1525–1527. doi: 10.1111/j.1476-5381.1995.tb14935.x

Functional evidence for a 5-HT2B receptor mediating contraction of longitudinal muscle in human small intestine.

R A Borman 1, D E Burleigh 1
PMCID: PMC1510406  PMID: 7599919

Abstract

Application of 5-hydroxytryptamine induces contraction of longitudinal muscle strips from human terminal ileum. The response was resistant to antagonism by ketanserin, ondansetron or DAU6285, but was non-surmountably antagonized by methysergide. The selective 5-HT2B/2C receptor antagonist, SB 200646A evoked a concentration-dependent, parallel and dextral displacement of the concentration-response curve to 5-HT, yielding a pA2 estimate of 7.17. Application of yohimbine, a 5-HT1 and 5-HT2B receptor antagonist, also induced a rightward shift of the response curve to 5-HT, yielding a pA2 estimate of 8.10. In conclusion, it appears that a 5-HT2B receptor mediates the contractile response of the longitudinal muscle of human small intestine to 5-HT.

Full text

PDF
1525

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baxter G. S., Murphy O. E., Blackburn T. P. Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle. Br J Pharmacol. 1994 May;112(1):323–331. doi: 10.1111/j.1476-5381.1994.tb13072.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Borman R. A., Burleigh D. E. Evidence for the involvement of a 5-HT4 receptor in the secretory response of human small intestine to 5-HT. Br J Pharmacol. 1993 Nov;110(3):927–928. doi: 10.1111/j.1476-5381.1993.tb13901.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kennett G. A., Wood M. D., Glen A., Grewal S., Forbes I., Gadre A., Blackburn T. P. In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist. Br J Pharmacol. 1994 Mar;111(3):797–802. doi: 10.1111/j.1476-5381.1994.tb14808.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Kursar J. D., Nelson D. L., Wainscott D. B., Baez M. Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor. Mol Pharmacol. 1994 Aug;46(2):227–234. [PubMed] [Google Scholar]
  5. Kursar J. D., Nelson D. L., Wainscott D. B., Cohen M. L., Baez M. Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus. Mol Pharmacol. 1992 Oct;42(4):549–557. [PubMed] [Google Scholar]
  6. Loric S., Launay J. M., Colas J. F., Maroteaux L. New mouse 5-HT2-like receptor. Expression in brain, heart and intestine. FEBS Lett. 1992 Nov 9;312(2-3):203–207. doi: 10.1016/0014-5793(92)80936-b. [DOI] [PubMed] [Google Scholar]
  7. Schiavone A., Giraldo E., Giudici L., Turconi M., Sagrada A. DAU 6285: a novel antagonist at the putative 5-HT4 receptor. Life Sci. 1992;51(8):583–592. doi: 10.1016/0024-3205(92)90227-g. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES